MX2009007429A - Compuestos de piridina y su uso como antagonistas de p2y12. - Google Patents

Compuestos de piridina y su uso como antagonistas de p2y12.

Info

Publication number
MX2009007429A
MX2009007429A MX2009007429A MX2009007429A MX2009007429A MX 2009007429 A MX2009007429 A MX 2009007429A MX 2009007429 A MX2009007429 A MX 2009007429A MX 2009007429 A MX2009007429 A MX 2009007429A MX 2009007429 A MX2009007429 A MX 2009007429A
Authority
MX
Mexico
Prior art keywords
antagonists
pyridine compounds
compounds
medicaments
inhibitors
Prior art date
Application number
MX2009007429A
Other languages
English (en)
Inventor
Fabrizio Giordanetto
David Brown
Peter Bach
Johan Johansson
Thomas Antonsson
Ruth Bylund
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39608896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007429(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2009007429A publication Critical patent/MX2009007429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a ciertos análogos nuevos del pyridin de la fórmula (i) con los procesos para preparar tales compuestos, con su utilidad como inhibidores P2Y12 y como agentes anti-tromboticos etc, su uso como medicamentos en enfermedades cardiovasculares así como las composiciones farmacéuticas que las contienen.
MX2009007429A 2007-01-12 2008-01-11 Compuestos de piridina y su uso como antagonistas de p2y12. MX2009007429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88465807P 2007-01-12 2007-01-12
PCT/SE2008/000017 WO2008085117A1 (en) 2007-01-12 2008-01-11 Pyridine compounds and their use as p2y12 antagonists.

Publications (1)

Publication Number Publication Date
MX2009007429A true MX2009007429A (es) 2009-07-17

Family

ID=39608896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007429A MX2009007429A (es) 2007-01-12 2008-01-11 Compuestos de piridina y su uso como antagonistas de p2y12.

Country Status (18)

Country Link
US (2) US20080171732A1 (es)
EP (1) EP2111400A4 (es)
JP (1) JP2010515728A (es)
KR (1) KR20090096742A (es)
AR (1) AR064866A1 (es)
AU (1) AU2008203953A1 (es)
BR (1) BRPI0806529A2 (es)
CA (1) CA2674998A1 (es)
CL (1) CL2008000091A1 (es)
CO (1) CO6190618A2 (es)
EC (1) ECSP099481A (es)
IL (1) IL199439A0 (es)
MX (1) MX2009007429A (es)
PE (1) PE20081633A1 (es)
RU (1) RU2009123928A (es)
TW (1) TW200833335A (es)
UY (1) UY30866A1 (es)
WO (1) WO2008085117A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008016551A (es) * 2006-07-04 2009-02-06 Astrazeneca Ab Analogos de piridina nuevos.
WO2010005384A1 (en) * 2008-07-07 2010-01-14 Astrazeneca Ab Ketone pyridine analogues and their use in the treatment of cardiovascular disorders
JP2014051434A (ja) * 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
RU2602456C1 (ru) * 2015-10-20 2016-11-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ оценки активности ароматазы овариальных фолликулов
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
KR102435080B1 (ko) 2016-07-19 2022-08-22 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 축합 바이시클릭 헤테로사이클 유도체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
JP3500429B2 (ja) * 2000-11-01 2004-02-23 現代自動車株式会社 ポリプロピレン樹脂組成物
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
ES2340179T3 (es) * 2004-05-12 2010-05-31 Bristol-Myers Squibb Company Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas.
EP1758580A4 (en) * 2004-06-24 2008-01-16 Incyte Corp N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT
EP1804819A4 (en) * 2004-10-04 2007-12-12 Univ Wayne State USE OF AROMATASE INHIBITORS FOR ENDOMETRIAL DILUTION IN THE PREPARATION OF SURGICAL PROCEDURES ON ENDOMETRIUM AND UTERUS
AU2006204159A1 (en) * 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
KR20080039405A (ko) * 2005-07-13 2008-05-07 아스트라제네카 아베 신규한 피리딘 유사체
CA2655629A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
MX2008016551A (es) * 2006-07-04 2009-02-06 Astrazeneca Ab Analogos de piridina nuevos.
EP2044024A4 (en) * 2006-07-04 2011-06-29 Astrazeneca Ab NEW ANALOGUES OF PYRIDINE

Also Published As

Publication number Publication date
BRPI0806529A2 (pt) 2014-04-22
EP2111400A4 (en) 2010-07-07
UY30866A1 (es) 2008-09-02
AU2008203953A1 (en) 2008-07-17
CO6190618A2 (es) 2010-08-19
PE20081633A1 (es) 2009-01-18
TW200833335A (en) 2008-08-16
RU2009123928A (ru) 2011-02-20
CL2008000091A1 (es) 2008-09-05
AR064866A1 (es) 2009-04-29
CA2674998A1 (en) 2008-07-17
ECSP099481A (es) 2009-08-28
EP2111400A1 (en) 2009-10-28
US20080171732A1 (en) 2008-07-17
KR20090096742A (ko) 2009-09-14
IL199439A0 (en) 2010-03-28
US20100137277A1 (en) 2010-06-03
WO2008085117A1 (en) 2008-07-17
JP2010515728A (ja) 2010-05-13

Similar Documents

Publication Publication Date Title
MX2007008237A (es) Compuestos de piridina novedosos.
TW200726758A (en) New pyridine analogues
HK1138840A1 (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
TW200740789A (en) Pyridine and pyrimidine derivatives as mGluR2 antagonists
TNSN07360A1 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY171553A (en) Pyrrolotriazinone derivatives as pi3k inhibitors
MX336381B (es) Boronatos como inhibidores de arginasa.
TW200639173A (en) Substituted pyrazolopyridines, compositions containing same, manufacturing process therefor and use thereof
MX2010012390A (es) Derivados de indazoles sustituidos con fenilo o piridinilo.
TW200732323A (en) Organic compounds
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
MX2012007175A (es) Derivados de imidazopiridina como inhibidores de jak.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TW200745084A (en) Novel compounds
IN2014CN04127A (es)
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
NZ590650A (en) Buprenorphine analogs
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2009010505A (es) Derivados de piridina y pirimidina como antagonistas de mglur2.
JO2673B1 (en) Diosmetin compounds, method of preparation and pharmaceutical compositions
MX2009007429A (es) Compuestos de piridina y su uso como antagonistas de p2y12.

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal